Investigation into the promoter DNA methylation of three genes (CAMK1D, CRY2 and CALM2) in the peripheral blood of patients with type 2 diabetes

Cheng,Jia; Tang,Linlin; Hong,Qingxiao; Ye,Huadan; Xu,Xuting; Xu,Leiting; Bu,Shizhong; Wang,Qinwen; Dai,Dongjun; Jiang,Danjie; Duan,Shiwei

doi:10.3892/etm.2014.1766

Investigation into the promoter DNA methylation of three genes (CAMK1D, CRY2 and CALM2) in the peripheral blood of patients with type 2 diabetes

Authors:
- Jia Cheng
- Linlin Tang
- Qingxiao Hong
- Huadan Ye
- Xuting Xu
- Leiting Xu
- Shizhong Bu
- Qinwen Wang
- Dongjun Dai
- Danjie Jiang
- Shiwei Duan
View Affiliations

Affiliations: Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, P.R. China
Published online on: June 6, 2014 https://doi.org/10.3892/etm.2014.1766
Pages: 579-584

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Promoter DNA methylation may reflect the interaction between genetic backgrounds and environmental factors in the development of metabolic disorders, including type 2 diabetes (T2D). Calcium/calmodulin‑dependent protein kinase 1D (CAMK1D), cryptochrome 2 (CRY2) and calmodulin 2 (CALM2) genes have been identified to be associated with a risk of T2D. Therefore, the aim of the present study was to investigate the contribution of promoter DNA methylation of these genes to the risk of T2D. Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age‑ and gender‑matched healthy controls. The results demonstrated that the promoters of these three genes were hypomethylated in the peripheral blood of all the subjects, and DNA methylation of these three genes did not contribute to the risk of T2D.

View Figures

View References

1	Volkmar M, Dedeurwaerder S, Cunha DA, et al: DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. EMBO J. 31:1405–1426. 2012. View Article : Google Scholar : PubMed/NCBI
2	Omori S, Tanaka Y, Takahashi A, et al: Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population. Diabetes. 57:791–795. 2008. View Article : Google Scholar : PubMed/NCBI
3	Gu T, Horová E, Möllsten A, et al: IGF2BP2 and IGF2 genetic effects in diabetes and diabetic nephropathy. J Diabetes Complications. 26:393–398. 2012. View Article : Google Scholar : PubMed/NCBI
4	Kwak SH, Kim SH, Cho YM, et al: A genome-wide association study of gestational diabetes mellitus in Korean women. Diabetes. 61:531–541. 2012. View Article : Google Scholar : PubMed/NCBI
5	Grarup N, Rose CS, Andersson EA, et al: Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies. Diabetes. 56:3105–3111. 2007. View Article : Google Scholar : PubMed/NCBI
6	Jia H, Yu L, Jiang Z and Ji Q: Association between IGF2BP2 rs4402960 polymorphism and risk of type 2 diabetes mellitus: a meta-analysis. Arch Med Res. 42:361–367. 2011. View Article : Google Scholar : PubMed/NCBI
7	Wu J, Wu J, Zhou Y, et al: Quantitative assessment of the variation in IGF2BP2 gene and type 2 diabetes risk. Acta Diabetol. 49(Suppl 1): S87–S97. 2012. View Article : Google Scholar : PubMed/NCBI
8	Toperoff G, Aran D, Kark JD, et al: Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood. Hum Mol Genet. 21:371–383. 2012. View Article : Google Scholar : PubMed/NCBI
9	Fraga MF, Ballestar E, Paz MF, et al: Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA. 102:10604–10609. 2005. View Article : Google Scholar : PubMed/NCBI
10	Barres R and Zierath JR: DNA methylation in metabolic disorders. Am J Clin Nutr. 93:897S–900S. 2011. View Article : Google Scholar : PubMed/NCBI
11	Barrès R, Osler ME, Yan J, et al: Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab. 10:189–198. 2009.PubMed/NCBI
12	Verploegen S, Ulfman L, van Deutekom HW, et al: Characterization of the role of CaMKI-like kinase (CKLiK) in human granulocyte function. Blood. 106:1076–1083. 2005. View Article : Google Scholar : PubMed/NCBI
13	Shu XO, Long J, Cai Q, et al: Identification of new genetic risk variants for type 2 diabetes. PLoS Genet. 6:e10011272010. View Article : Google Scholar : PubMed/NCBI
14	Imamura M, Iwata M, Maegawa H, et al: Genetic variants at CDC123/CAMK1D and SPRY2 are associated with susceptibility to type 2 diabetes in the Japanese population. Diabetologia. 54:3071–3077. 2011. View Article : Google Scholar : PubMed/NCBI
15	Schleinitz D, Tönjes A, Böttcher Y, et al: Lack of significant effects of the type 2 diabetes susceptibility loci JAZF1, CDC123/CAMK1D, NOTCH2, ADAMTS9, THADA, and TSPAN8/LGR5 on diabetes and quantitative metabolic traits. Horm Metab Res. 42:14–22. 2010. View Article : Google Scholar : PubMed/NCBI
16	Murea M, Lu L, Ma L, et al: Genome-wide association scan for survival on dialysis in African-Americans with type 2 diabetes. Am J Nephrol. 33:502–509. 2011. View Article : Google Scholar : PubMed/NCBI
17	Dupuis J, Langenberg C, Prokopenko I, et al: New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 42:105–116. 2010. View Article : Google Scholar : PubMed/NCBI
18	Ribel-Madsen R, Fraga MF, Jacobsen S, et al: Genome-wide analysis of DNA methylation differences in muscle and fat from monozygotic twins discordant for type 2 diabetes. PLoS One. 7:e513022012. View Article : Google Scholar : PubMed/NCBI
19	Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 15:539–553. 1998. View Article : Google Scholar : PubMed/NCBI
20	García-Giménez JL, Sanchis-Gomar F, Lippi G, et al: Epigenetic biomarkers: A new perspective in laboratory diagnostics. Clin Chim Acta. 413:1576–1582. 2012.PubMed/NCBI
21	Zampetaki A, Kiechl S, Drozdov I, et al: Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 107:810–817. 2010. View Article : Google Scholar : PubMed/NCBI
22	Zhao C, Dong J, Jiang T, et al: Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One. 6:e239252011. View Article : Google Scholar : PubMed/NCBI
23	Dehwah MA, Xu A and Huang Q: MicroRNAs and type 2 diabetes/obesity. J Genet Genomics. 39:11–18. 2012. View Article : Google Scholar : PubMed/NCBI
24	Poy MN, Eliasson L, Krutzfeldt J, et al: A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 432:226–230. 2004. View Article : Google Scholar : PubMed/NCBI
25	Husseiny MI, Kuroda A, Kaye AN, Nair I, Kandeel F and Ferreri K: Development of a quantitative methylation-specific polymerase chain reaction method for monitoring beta cell death in type 1 diabetes. PLoS One. 7:e479422012. View Article : Google Scholar : PubMed/NCBI
26	Kong L, Zhu J, Han W, et al: Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 48:61–69. 2011. View Article : Google Scholar : PubMed/NCBI